蔚蓝生物
(603739)
| 流通市值：24.54亿 | | | 总市值：24.54亿 |
| 流通股本：2.53亿 | | | 总股本：2.53亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 228,361,214.3 | 279,620,817.25 | 188,103,617.55 | 213,869,787.07 |
| 应收票据及应收账款 | 322,888,184.16 | 288,298,029.27 | 262,757,777.43 | 304,483,025.58 |
| 其中：应收票据 | 5,192,371.5 | 1,366,739.68 | 3,946,512 | 5,896,612 |
| 应收账款 | 317,695,812.66 | 286,931,289.59 | 258,811,265.43 | 298,586,413.58 |
| 应收款项融资 | - | 3,897,729 | 2,278,722.58 | 3,238,569.05 |
| 预付款项 | 17,563,650.78 | 18,214,794.49 | 21,228,099.78 | 14,651,825.13 |
| 其他应收款合计 | 39,027,195.14 | 40,356,339.27 | 38,334,389.54 | 32,508,039.7 |
| 其中:应收利息 | - | - | - | 36,821.92 |
| 存货 | 186,393,061.31 | 184,595,707.49 | 186,588,269.25 | 173,633,590.12 |
| 其他流动资产 | 23,475,074.97 | 28,269,288.93 | 20,939,955.93 | 14,994,905.82 |
| 流动资产平衡项目 | 0 | 0 | 0.01 | 0 |
| 流动资产合计 | 1,136,872,000.39 | 1,100,929,315.12 | 975,341,333.35 | 969,399,325.09 |
| 非流动资产: | | | | |
| 长期股权投资 | 76,411,770.47 | 71,920,842.14 | 74,587,891.29 | 73,844,042.21 |
| 其他权益工具投资 | 3,345,139.12 | 3,345,139.12 | 3,345,139.12 | 3,345,139.12 |
| 固定资产 | 535,833,169.16 | 532,992,533.72 | 543,762,152.51 | 555,451,474.28 |
| 在建工程 | 805,170,720.87 | 800,729,335.52 | 758,374,934.98 | 704,430,069.57 |
| 无形资产 | 133,567,953.26 | 133,457,321.83 | 133,580,043.65 | 135,631,632.97 |
| 商誉 | 85,330,116.11 | 20,257,069.43 | 20,257,069.43 | 20,257,069.43 |
| 长期待摊费用 | 1,914,799.36 | 1,477,979.11 | 1,285,779.72 | 1,279,870.3 |
| 递延所得税资产 | 15,697,762.99 | 14,429,030.52 | 13,863,572.47 | 13,636,252.55 |
| 其他非流动资产 | 131,929,971.99 | 118,246,949.6 | 105,569,113.39 | 101,572,761.46 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,789,201,403.33 | 1,696,856,200.99 | 1,654,625,696.56 | 1,609,448,311.89 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,926,073,403.72 | 2,797,785,516.11 | 2,629,967,029.91 | 2,578,847,636.98 |
| 流动负债: | | | | |
| 短期借款 | 557,711,519.1 | 553,335,553.1 | 418,012,123.29 | 374,215,958.91 |
| 应付票据及应付账款 | 139,957,731.13 | 144,496,797.93 | 139,949,040.93 | 147,357,052.72 |
| 其中：应付票据 | 10,530,160 | 12,154,800 | 7,179,800 | 6,614,000 |
| 应付账款 | 129,427,571.13 | 132,341,997.93 | 132,769,240.93 | 140,743,052.72 |
| 合同负债 | 8,399,956.97 | 9,110,142 | 11,585,457.45 | 7,488,230.9 |
| 应付职工薪酬 | 32,571,821.16 | 23,532,118.07 | 13,200,762.45 | 30,902,774.48 |
| 应交税费 | 15,375,210.2 | 9,702,602.84 | 11,124,397.43 | 26,472,675.85 |
| 其他应付款合计 | 117,514,335.8 | 64,941,716.68 | 51,066,425.21 | 50,626,145.05 |
| 其他流动负债 | 16,340,958.25 | 20,854,723.29 | 13,400,529.03 | 8,022,673.39 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 887,871,532.61 | 825,973,653.91 | 658,338,735.79 | 645,085,511.3 |
| 非流动负债: | | | | |
| 长期借款 | 171,900,000 | 171,900,000 | 179,000,000 | 149,000,000 |
| 长期应付款 | 172,000 | 172,000 | 172,000 | 172,000 |
| 递延收益 | 51,652,476.44 | 51,069,993.94 | 44,635,400.14 | 47,955,100.57 |
| 递延所得税负债 | 2,852,646.26 | 2,635,138.98 | 2,598,762.12 | 2,721,619.31 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 226,577,122.7 | 225,777,132.92 | 226,406,162.26 | 199,848,719.88 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,114,448,655.31 | 1,051,750,786.83 | 884,744,898.05 | 844,934,231.18 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 253,028,866 | 252,638,866 | 252,621,666 | 252,441,726 |
| 资本公积 | 721,373,856.79 | 710,729,584.99 | 710,458,653.8 | 705,093,098.69 |
| 其他综合收益 | -16,870,226.11 | -16,781,999.31 | -17,004,982.54 | -16,959,871.73 |
| 盈余公积 | 47,533,813.81 | 47,533,813.81 | 47,533,813.81 | 47,533,813.81 |
| 未分配利润 | 686,644,787.83 | 662,806,130.57 | 667,148,370.99 | 656,585,615.62 |
| 归属于母公司股东权益平衡项目 | 0.01 | 0 | 0.01 | 0 |
| 归属于母公司股东权益合计 | 1,691,711,098.33 | 1,656,926,396.06 | 1,660,757,522.07 | 1,644,694,382.39 |
| 少数股东权益 | 119,913,650.08 | 89,108,333.22 | 84,464,609.79 | 89,219,023.41 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,811,624,748.41 | 1,746,034,729.28 | 1,745,222,131.86 | 1,733,913,405.8 |
| 负债和股东权益合计 | 2,926,073,403.72 | 2,797,785,516.11 | 2,629,967,029.91 | 2,578,847,636.98 |
| 公告日期 | 2023-10-28 | 2023-08-25 | 2023-04-27 | 2023-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |